{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:04:27Z","timestamp":1768003467367,"version":"3.49.0"},"reference-count":17,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2002,10,29]],"date-time":"2002-10-29T00:00:00Z","timestamp":1035849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2003,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We report on a patient with genetically proven Machado\u2010Joseph Disease (MJD) presenting with signs indistinguishable from Parkinson's disease (PD), including levodopa response and typical levodopa\u2010induced motor fluctuations. Only after 10 years of prolonged benefit from levodopa and different dopamine agonists (DA), the patient developed cerebellar ataxia and pyramidal signs. Preferential D3\u2010receptor\u2013stimulating dopamine agonists especially showed a benefit at the time, when D2 receptor binding was reduced in IBZM SPECT. This is the first report of a meaningful response to DA in MJD. \u00a9 2002 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.10322","type":"journal-article","created":{"date-parts":[[2003,1,22]],"date-time":"2003-01-22T17:16:26Z","timestamp":1043255786000},"page":"219-221","source":"Crossref","is-referenced-by-count":58,"title":["Dopaminergic response in Parkinsonian phenotype of Machado\u2010Joseph disease"],"prefix":"10.1002","volume":"18","author":[{"given":"Carsten","family":"Buhmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Bussopulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Oechsner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,10,29]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870110625"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.58.2.296"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410380422"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1984.04050200027013"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197706302962606"},{"key":"e_1_2_5_7_2","first-page":"33","article-title":"Joseph's disease: an autosomal dominant neurological disease in the Portuguese of the United States and the Azores Islands","volume":"21","author":"Rosenberg RN","year":"1978","journal-title":"Adv Neurol"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.57.10.1495"},{"key":"e_1_2_5_9_2","first-page":"994","article-title":"Decreased dopamine transporter binding in Machado\u2010Joseph disease","volume":"41","author":"Yen TC","year":"2000","journal-title":"J Nucl Med"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(96)00242-0"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.4.1133"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(98)00896-6"},{"key":"e_1_2_5_13_2","first-page":"141","article-title":"Pharmacology of pramipexole, a dopamine D3\u2010preferring agonist useful in treating Parkinson's disease","volume":"21","author":"Piercey MF","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1353-8020(00)00062-6"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s007020070001"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100000068"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(89)90031-0"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(98)00066-9"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.10322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:59:52Z","timestamp":1760961592000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.10322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10,29]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,2]]}},"alternative-id":["10.1002\/mds.10322"],"URL":"https:\/\/doi.org\/10.1002\/mds.10322","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,10,29]]}}}